Last reviewed · How we verify
Fast CAR T cells
At a glance
| Generic name | Fast CAR T cells |
|---|---|
| Sponsor | Shanghai Cell Therapy Group Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE (PHASE1)
- Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (PHASE1)
- Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE (PHASE1)
- Tisagenlecleucel In Primary CNS Lymphoma (PHASE1)
- Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (PHASE1)
- A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer (EARLY_PHASE1)
- Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE (PHASE1)
- Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fast CAR T cells CI brief — competitive landscape report
- Fast CAR T cells updates RSS · CI watch RSS
- Shanghai Cell Therapy Group Co.,Ltd portfolio CI